High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

There are currently few approved effective treatments for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Nanobodies are 12–15 kDa single-domain antibody fragments that can be delivered by inhalation and are amenable to relatively inexpensive large scale production compared to other bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Esparza, Thomas J., Martin, Negin P., Anderson, George P., Goldman, Ellen R., Brody, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755911/
https://www.ncbi.nlm.nih.gov/pubmed/33353972
http://dx.doi.org/10.1038/s41598-020-79036-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755911/
https://www.ncbi.nlm.nih.gov/pubmed/33353972
http://dx.doi.org/10.1038/s41598-020-79036-0

Ejemplares similares